Discovery of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent and selective heparanase-1 inhibitor utilizing an improved synthetic approach.

2-a]pyridine-5-carboxylic acid Heparanase-1 inhibitor Imidazole synthesis Tetrahydroimidazo[1

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 Jan 2024
Historique:
received: 14 09 2023
revised: 25 10 2023
accepted: 03 11 2023
pubmed: 9 11 2023
medline: 9 11 2023
entrez: 8 11 2023
Statut: ppublish

Résumé

Heparanase-1 (HPSE1) is an endo-β-d-glucuronidase that catalyzes degradation of heparan sulfate proteoglycans. Inhibition of HPSE1 appears to be a useful therapeutic target against cancer and proteinuric kidney diseases. We previously reported tetrahydroimidazo[1,2-a]pyridine 2 as a potent HPSE1 inhibitor after optimization of the synthetic reaction. However, synthesis of 2 involves a total of 19 steps, including a cyclization process that accompanies a strong odor due to the use of Lawesson's reagent and an epimerization reaction; furthermore, 2 exhibited insufficient selectivity for HPSE1 over exo-β-d-glucuronidase (GUSβ) and glucocerebrosidase (GBA), which also needed to be addressed. First, the cyclization reaction was optimized to synthesize tetrahydroimidazo[1,2-a]pyridine without using Lawesson's reagent or epimerization, with reference to previous reports. Next, 16 and 17 containing a bulkier substituent at position 6 than the 6-methoxyl group in 2 were designed and synthesized using the improved cyclization conditions, so that the synthetic route of 16 and 17 was shortened by five steps as compared with that of 2. The inhibitory activities of 16 and 17 against GUSβ and GBA were reduced as compared with those of 2, that is, the compounds showed improved selectivity for HPSE1 over GUSβ and GBA. In addition, 16 showed enhanced inhibitory activity against HPSE1 as compared with that of 2. Compound 16 appears promising as an HPSE1 inhibitor with therapeutic potential due to its highly potent inhibitory activity against HPSE1 with high selectivity for HPSE1.

Identifiants

pubmed: 37939863
pii: S0960-894X(23)00421-3
doi: 10.1016/j.bmcl.2023.129543
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

129543

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yudai Imai (Y)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Ryo Suzuki (R)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Daisuke Matsuda (D)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Nozomi Tanaka-Yamamoto (N)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Yuta Ohki (Y)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Ryotaro Tabata (R)

Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Sota Kato (S)

Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Mami Sugisaki (M)

Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Natsuko Fujimoto (N)

Discovery Technologies Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Takuya Fukunaga (T)

Discovery Technologies Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Sayaka Kato (S)

Discovery Technologies Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Teisuke Takahashi (T)

Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.

Hiroyuki Kakinuma (H)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan. Electronic address: h-kakinuma@taisho.co.jp.

Classifications MeSH